{"name": "Acorda Therapeutics",
 "permalink": "acorda-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/acorda-therapeutics",
 "homepage_url": "http://www.acorda.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@acorda.com",
 "phone_number": "914-347-4300",
 "description": "",
 "created_at": "Mon Jul 04 02:23:27 UTC 2011",
 "updated_at": "Sat Feb 18 02:32:28 UTC 2012",
 "overview": "\u003Cp\u003EAcorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda\u00e2\u20ac\u2122s marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       48],
      "assets/images/resized/0014/2338/142338v1-max-150x150.png"],
     [[177,
       57],
      "assets/images/resized/0014/2338/142338v1-max-250x250.png"],
     [[177,
       57],
      "assets/images/resized/0014/2338/142338v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Ron",
      "last_name": "Cohen",
      "permalink": "ron-cohen",
      "image": null}},
   {"is_past": false,
    "title": "Vice President, Finance",
    "person":
     {"first_name": "Jennifer",
      "last_name": "Burstein",
      "permalink": "jennifer-burstein",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 130000000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020120217e82hul7nu\u0026r=Rss\u0026s=DJFVW",
    "source_description": "Acorda Thera Acquiring Neuronex In Deal Potentially Worth Over $130M ",
    "acquired_year": 2012,
    "acquired_month": 2,
    "acquired_day": 17,
    "company":
     {"name": "Neuronex",
      "permalink": "neuronex",
      "image":
       {"available_sizes":
         [[[150,
            29],
           "assets/images/resized/0010/4652/104652v1-max-150x150.png"],
          [[250,
            49],
           "assets/images/resized/0010/4652/104652v1-max-250x250.png"],
          [[387,
            76],
           "assets/images/resized/0010/4652/104652v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "15 Skyline Drive",
    "address2": "",
    "zip_code": "10532 ",
    "city": "Hawthorne",
    "state_code": "NY",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Acorda snags Ph2 neurological trauma program in $35M deal",
    "stoned_year": 2011,
    "stoned_month": 7,
    "stoned_day": 1,
    "source_url": "http://www.fiercebiotech.com/story/acorda-snags-ph2-neurological-trauma-program-35m-deal/2011-07-01?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Acorda snags Ph2 neurological trauma program in $35M deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Acorda Therapeutics",
      "permalink": "acorda-therapeutics"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:ACOR"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}